Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
News > Health News
Audio By Carbonatix
7:00 AM on Thursday, August 21
The Associated Press
HOUSTON--(BUSINESS WIRE)--Aug 21, 2025--
Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings.
The webcast of the fireside chat will be accessible on the Tvardi Investors’ website. A replay of the webcast will be available for approximately 90 days following the conference.
About Tvardi Therapeutics
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis ( NCT05671835 ) and hepatocellular carcinoma ( NCT05440708 ). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
View source version on businesswire.com:https://www.businesswire.com/news/home/20250821001327/en/
CONTACT: For Tvardi:
Tvardi Investor Relations
[email protected] Kelleher
LifeSci Advisors
617-430-7579
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH
SOURCE: Tvardi Therapeutics, Inc.
Copyright Business Wire 2025.
PUB: 08/21/2025 08:00 AM/DISC: 08/21/2025 07:59 AM
http://www.businesswire.com/news/home/20250821001327/en
